Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexmedetomidine + levobupivacaine is a combination used primarily in regional anesthesia, especially for nerve blocks such as axillary or supraclavicular brachial plexus block. Dexmedetomidine is an alpha-2 adrenergic receptor agonist that provides sedative, anxiolytic, and analgesic effects without significant respiratory depression. Levobupivacaine is a long-acting amide local anesthetic that blocks sodium channels to inhibit nerve impulse transmission and provide local anesthesia. When combined, dexmedetomidine acts as an adjuvant to levobupivacaine, shortening the onset time of sensory and motor blockades while significantly prolonging their duration and extending postoperative analgesia. This combination can also reduce the required dose of local anesthetic and may improve patient comfort by reducing postoperative pain scores[1][2][7]. However, it may be
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine + levobupivacaine.